SCHEMBL2424845

SCHEMBL2424845

CC(O)Cc1ccc(Cl)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.50
CYP3A4 P08684 4/20 0.48
CYP1A2 P05177 3/20 0.48
CYP2C19 P33261 3/20 0.48
CYP2C9 P11712 3/20 0.48
MAPK1 P28482 1/20 0.48
CYP2D6 P10635 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALOX15 P16050 2/20 0.47
EPHX1 P07099 1/20 0.46
HDAC8 Q9BY41 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALOX12 P18054 1/20 0.46
GAA P10253 1/20 0.45
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GGPS1 O95749 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15084293 1.00 IDO1 (0.50) IDO1CYP3A4CYP1A2CYP2C19CYP2C9
SCHEMBL15083013 0.85 EPHX1 (0.48) IDO1CYP3A4CYP1A2CYP2C19CYP2C9
SCHEMBL2659771 0.83 IDO1 (0.54) IDO1CYP3A4CYP1A2CYP2C19CYP2C9
SCHEMBL5950406 0.82 PNMT (0.47) CYP3A4CYP1A2CYP2C19CYP2C9MAPK1
SCHEMBL7913322 0.82 IDO1 (0.52) IDO1CYP3A4CYP1A2CYP2C19CYP2C9
SCHEMBL8422598 0.82 IDO1 (0.52) IDO1CYP3A4CYP1A2CYP2C19CYP2C9
SCHEMBL3437067 0.81 IDO1 (0.47) IDO1CYP3A4CYP1A2CYP2C19CYP2C9
SCHEMBL10587522 0.81 TYR (0.51) IDO1CYP3A4CYP1A2CYP2C19CYP2C9
SCHEMBL3237063 0.81 IDO1 (0.47) IDO1CYP3A4CYP1A2CYP2C19CYP2C9
SCHEMBL10587518 0.81 IDO1 (0.47) IDO1CYP3A4CYP1A2CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265616-B1 FURO-AND THIENO[3,2-C]PYRIDINES OSI PHARM INC (US) 2013-11-20 EP disclosed
CN-101175482-B Abuse-proofed dosage form GRUENENTHAL GMBH 2013-09-18 CN disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
EP-2265616-A1 FURO-AND THIENO[3,2-C]PYRIDINES OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009100282-A1 FURO-AND THIENO[3,2-C] PYRIDINES OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed
CN-101175482-A Abuse-proofed dosage form GRUENENTHAL GMBH (DE) 2008-05-07 CN disclosed
US-4040977-A HALOACETAMIDE OR THIOCYANOACETAMIDE-ALCOHOL-FORMALDEHYDE CONDENSATES STERLING DRUG INC. (US) 1977-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines RET, MET, ERBB2 IDO1 3179/4885CYP3A4 1314/4885CYP1A2 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.